Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Geomerics Update

26 Mar 2012 07:00

RNS Number : 9988Z
Angle PLC
26 March 2012
 



For immediate release

26 March 2012

 

ANGLE plc

 

("ANGLE" or the "Company")

 

GEOMERICS EXPANDS PRODUCT RANGE AND SALES

 

 

ANGLE plc (AIM: AGL), the technology commercialisation company, is pleased to announce positive progress in new products, sales and market recognition at its 33%-owned portfolio company Geomerics, which specialises in computer games middleware.

 

At the recent Game Developers Conference (GDC 2012) in San Francisco, Geomerics announced the development of new products for mobile devices and for Nintendo's new Wii™ U console. These new products significantly expand the addressable market for Geomerics products.

 

The company demonstrated a range of new technologies aimed at rounding out the Enlighten offering and getting 'next gen ready'. In partnership with ARM, they showcased Enlighten running smoothly on a Mali-based Samsung Galaxy Tab 7.7 tablet on the expo floor. This is an expansion of Geomerics' product capability and Enlighten, via ARM CPU, now supports a wide range of mobile devices including the iOS-based iPad and iPhone, Android devices and PlayStation® Vita, offering new sales opportunities.

 

Geomerics also announced its new product capability for Nintendo's new Wii™ U console, the successor to the highly successful Wii™ adding to its capability on the PC, PS3 and Xbox360. Geomerics also displayed on the NVIDIA and Intel booths at GDC 2012, reaffirming their commitment to high-end gaming experiences on the PC and console.

 

Geomerics sales continue to strengthen. Since GDC 2012 finished on 9th March, Geomerics has already been notified of four new sales for major new games, three of which are to entirely new customers, and its pipeline of prospective customers is steadily increasing.

 

Finally, there has been further market recognition for Geomerics' Enlighten with a BAFTA award being won by a computer game incorporating the Enlighten lighting solution.

 

The British Academy of Film and Television Arts (BAFTA) 2011 GAME Award has been awarded to Battlefield 3, an Electronic Arts game incorporating Enlighten. The GAME Award recognises the best game of the year, and is the only category at the British Academy Video Games Awards to be voted for by the general public.

 

Battlefield 3 is the fastest selling Electronic Arts game ever, selling more than 5 million units in its first week of release. Enlighten is the only real-time global illumination solution available for computer games, enabling the lighting to be realistically calculated in real-time as the player interacts with the game environment and other players. As a result, Enlighten provides a much more realistic player experience.

 

The reviews of Battlefield 3 have frequently singled out the lighting. For example The Guardian reported "Visually Battlefield 3 is a marvel of beautiful lighting effects" and GameSpy in its review said "Once they see the light - they'll understand what a special game Battlefield 3 is". The quality of the lighting and graphics in general has been a major contributor to the success of the game.

 

In a first time win at the BAFTA awards for the Battlefield franchise, it beat titles including FIFA 12, The Elder Scrolls V: Skyrim and Batman: Arkham City. Also, for the first time Battlefield beat the long-standing favourite Call of Duty, which has dominated the GAME Award for the past three years.

 

 

Gary Lewis, Chief Executive of Geomerics, commented:

"The BAFTA award for Battlefield 3 is an excellent further endorsement of the success of the game. We are pleased with ongoing adoption of the Enlighten technology in major new games. 2012 looks like being a great year for us and the expansion into mobile computing offers substantial growth potential for the future."

 

 

Andrew Newland, Chief Executive of ANGLE commented:

"We are delighted by Geomerics' ongoing success and believe the company is positioned well for the future."

 

 

 

 

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Cenkos Securities

Stephen Keys, Adrian Hargrave (Nominated adviser)

Andy Roberts (Sales)

 

020 7397 8900

Buchanan

Mark Court, Sophie Cowles

 

020 7466 5000

Scott Harris

Stephen Scott, Harry Dee

0207 653 0030

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQXLFLLXFFBBL
Date   Source Headline
26th Mar 20184:35 pmRNSPrice Monitoring Extension
26th Mar 20187:00 amRNSResearch Update
6th Feb 20187:00 amRNSANGLE plc: RESEARCH GRANT FROM ABBOTT
31st Jan 20187:00 amRNSInterim Results
16th Jan 20187:00 amRNSWEBINAR:USING PARSORTIX TO TEST DRUGS ON LIVE CTCS
10th Jan 201810:16 amRNSNotice of Results
8th Jan 20187:00 amRNSANGLE plc:Prostate cancer ARV7 treatment biomarker
27th Dec 201711:49 amRNSHolding(s) in Company
12th Dec 20177:00 amRNSTransfer of Lock-in Shares
8th Dec 20177:00 amRNSPARSORTIX POTENTIAL IN METASTATIC BREAST CANCER
28th Nov 20177:00 amRNSParsortix enables CTC molecular characterisation
23rd Nov 20177:00 amRNSPHILIPS COLLABORATION IN BREAST AND RECTAL CANCER
17th Nov 20174:06 pmRNSHolding(s) in Company
16th Nov 20178:23 amRNSTotal Voting Rights and Covington Subscription
6th Nov 20177:00 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSHolding(s) in Company
2nd Nov 201710:04 amRNSHolding(s) in Company
1st Nov 20178:12 amRNSANGLE: Completion of Fundraising and Acquisition
31st Oct 20172:18 pmRNSResult of AGM
30th Oct 201710:31 amRNSResult of General Meeting
26th Oct 20178:10 amRNSTotal Voting Rights
23rd Oct 20177:00 amRNSParsortix harvests cancer cells from bone marrow
20th Oct 20173:05 pmRNSNotice of AGM
17th Oct 20177:00 amRNSANGLE: 7th Peer Reviewed Publication On Parsortix
12th Oct 20177:00 amRNSProposed further subscription for £2.8 million
9th Oct 20177:02 amRNSCTCs harvested with Parsortix grown in laboratory
9th Oct 20177:01 amRNSPotential new analytical protocol using Parsortix
9th Oct 20177:00 amRNSParsortix Showcased at CTC Conference
5th Oct 201711:46 amRNSResults of Fundraising
5th Oct 20177:00 amRNSAcquisition and Fundraising
13th Sep 20175:36 pmRNSHolding(s) in Company
13th Sep 20177:00 amRNSExclusive worldwide option over megakaryocyte IP
11th Sep 20177:00 amRNSCo-Marketing Partnership with QIAGEN
5th Sep 20177:00 amRNSChange of Adviser
4th Sep 20177:00 amRNSNew Research with Parsortix
27th Jul 20177:00 amRNSPreliminary Results
20th Jul 20171:00 pmRNSPreclinical Study Presented At Tumor Boston Summit
6th Jul 201710:05 amRNSNotice of Results
4th Jul 20177:00 amRNSSuccessful Headline Data in Ovarian Cancer Studies
15th Jun 20177:00 amRNSParsortix breakthrough in prostate cancer
5th Jun 20177:00 amRNSSuccess with Parsortix in Colorectal Cancer
3rd May 20177:00 amRNSBusiness Update
4th Apr 20177:00 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSParsortix enables analysis in head and neck cancer
30th Mar 20177:00 amRNSProstate Cancer Update
14th Feb 201711:39 amEQSEdison issues outlook on Angle
13th Feb 20177:00 amRNSSelected for European Cancer ID Programme
26th Jan 20177:01 amRNSInterim Evaluation of Ovarian Cancer Study
26th Jan 20177:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.